Goodbody Health Limited.
(“Goodbody Health”, or the “Company”)

Result of Annual General Meeting and Withdrawal from AQSE

Goodbody Health (AQSE: GDBY) is pleased to announce the results of the Company’s Annual General Meeting of the shareholders held today, on 12^th May 2022 (the “Meeting”). At the Meeting there were 9,774,809 ordinary shares represented in person or by proxy and voted or withheld votes, representing 26.8% of the total ordinary shares issued and outstanding.  A majority of the ordinary shares that voted were to accept all proposed resolutions as follows:

Resolution 1 – To accept the financial statements. For 9,732,965 (99.8%), Against 22,087 (0.2%)

Resolution 2 – That the directors be authorised to appoint the auditors for year ending 31 December 2023 and determine their remuneration. For 9,732,525 (99.7%), Against 27,464 (0.3%)

Resolution 3 – That the directors are authorised to allot ordinary shares or to convert relevant securities up to 18,300,000. For 8,957,097 (91.8%), Against 802,244 (8.2%)

Resolution 4 – That the articles were amended to allow the board to issue securities by special resolution. For 8,930,688 (91.5%), Against 828,653 (8.5%)

Resolution 5 – That the Directors are allowed to allot 18,300,000 ordinary shares for cash. For 8,913,935 (91.3%), Against 845,406 (8.7%)

Resolution 6 – That the admission to the AQSE of the Company’s ordinary shares be cancelled. For 8,925,019 (91.4%), Against 840,812 (8.6%)

As the cancellation of the admission of the ordinary shares to the AQSE Growth Market has been passed by more than 75% of those Shareholders voting, the final day of trading on the AQSE Growth Market will be Monday, 15^th May 2023, and the cancellation will take effect from the market opening on 16^th May 2023. 

From 16th May 2023, the ordinary shares in Goodbody Health Limited will be admitted to trading on JP Jenkins share dealing platform.  

JP Jenkins is the longest established trading platform in UK for unlisted or unquoted companies, enabling shareholders and prospective investors to transact on a matched bargain basis.

Should shareholders wish to trade their ordinary shares they can do so through their stockbroker. The indicative price and transaction history are available on JP Jenkins’s website (https://jpjenkins.com). For more information, please call +44 (0) 20 7469 0937.